Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gilberto Mendoza

Cardiovascular Disease San Juan, PR Medical Doctor

NPI 1386784924 CMS profile 289256

369 Calle De Diego, Suite 510, San Juan, PR 00923

Open in the dashboard

General payments

$5,139

115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gilberto Mendoza of San Juan, PR is reported in the CMS Open Payments database as having received $5,139 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $543 18
2024 General $236 8
2023 General $646 17
2022 General $333 11
2021 General $411 24
2020 General $258 15
2019 General $2,711 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gilberto Mendoza
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Gilberto Mendoza were reported at $543. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Gilberto Mendoza Cardiovascular Disease median Middle half National median
2019 $2,711 $450 $127–$1,392 $163
2020 $258 $242 $77–$751 $114
2021 $411 $335 $101–$1,037 $132
2022 $333 $395 $121–$1,211 $149
2023 $646 $443 $136–$1,283 $160
2024 $236 $450 $136–$1,323 $164
2025 $543 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $2,957 40 payments
  2. AstraZeneca Pharmaceuticals LP $343 20 payments
  3. E.R. Squibb & Sons, L.L.C. $308 7 payments
  4. Boston Scientific Corporation $307 5 payments
  5. Amgen Inc. $284 10 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $213 6 payments
  7. PBG Puerto Rico LLC $172 10 payments
  8. Abbott Laboratories $165 7 payments
  9. Medtronic, Inc. $134 1 payment
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $116 2 payments
  11. Other $140 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,036 112 payments
  2. Consulting Fee $2,080 1 payment
  3. Travel and Lodging $17 1 payment
  4. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $2,929 38 payments
  2. CAMZYOS $256 3 payments
  3. FARXIGA $159 9 payments
  4. Repatha Cardiology $149 7 payments
  5. WATCHMAN FLX $136 1 payment
  6. REPATHA Cardiovascular $135 3 payments
  7. COREVALVE EVOLUT R $134 1 payment
  8. JARDIANCE $127 2 payments
  9. ELIQUIS $122 7 payments
  10. LOKELMA $117 6 payments
  11. Other $984 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 84 drugs

Part D claims

9,333

Median for Cardiology: 2,533

Drug cost

$774,598

Median for Cardiology: $485,213

Branded share of claims

23.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 339 $242,222
Xarelto Rivaroxaban Brand 114 $121,323
Jardiance Empagliflozin Brand 59 $64,546
Farxiga Dapagliflozin Propanediol Brand 48 $35,102
Candesartan Cilexetil Generic 256 $33,910
Synthroid Levothyroxine Sodium Brand 250 $31,059
Brilinta Ticagrelor Brand 28 $29,573
Entresto Sacubitril/Valsartan Brand 12 $22,904
Metoprolol Succinate Generic 829 $18,243
Repatha Sureclick Evolocumab Brand 22 $17,867

The 10 drugs with the highest cost, of 84 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$7,489

Medicare's payments for the services billed

Medicare patients

36

Average age 79

Services billed

163

22 women, 14 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Heart failure 50%
Arthritis 50%
Chronic kidney disease 42%
Ischemic heart disease 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $102
$102 59 —
XARELTO
  • Janssen Pharmaceuticals, Inc $80
$80 114 —
LOKELMA
  • AstraZeneca Pharmaceuticals LP $37
$37 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $17
$17 48 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record